Ankylosing spondylitis
Conference Coverage
TNF inhibitors slow hip deterioration in ankylosing spondylitis
Key clinical point: Ankylosing spondylitis patients on tumor necrosis factor inhibitor treatment had substantially better maintenance of hip...
Conference Coverage
Routine cardiac screening in spondyloarthritis shown unneeded
Key clinical point: Patients with axial spondyloarthritis or ankylosing spondylitis had no excess prevalence of structural cardiac abnormalities...
News
FDA accepting comments on draft guidelines on compounding law
The Food and Drug Administration is accepting comments on plans to implement a law to restrict compounding of human drug products.
News
FDA advisory panel unanimously backs biosimilars for Humira, Enbrel
News
Radiographic vertebral fractures common in ankylosing spondylitis patients
News
Adalimumab approved to treat noninfectious uveitis
Commentary
Pharma jousts statistically for an ankylosing spondylitis edge
Conference Coverage
NSAID plus TNFi linked to less ankylosing spondylitis progression
Key clinical point: Ankylosing spondylitis patients treated with a TNF inhibitor plus an NSAID had the lowest level of new bone formation during...
Conference Coverage
NSAID plus TNFi linked to less ankylosing spondylitis progression
Key clinical point: Ankylosing spondylitis patients treated with a TNF inhibitor plus an NSAID had the lowest level of new bone formation during...
Conference Coverage
VIDEO: Updated axial SpA recommendations include IL-17 inhibitors
The option of treating axial spondyloarthritis with an interleukin-17 inhibitor has become an officially recommended option for the first time in...
Conference Coverage
Secukinumab may slow structural ankylosing spondylitis progression
Key clinical point: Ankylosing spondylitis patients maintained on open-label secukinumab treatment for 2 years showed a low level of structural...